维奥欣治疗脑血管疾病的临床循证研究  

Systematic Review of Shuyuzaogan Tablet for Coronary Heart Disease

作　　者：张朕华[1] 

机构地区：[1]上海医药工业研究院,上海200040

出　　处：《中国医药指南》2011年第23期177-178,共2页Guide of China Medicine

基　　金：国家"重大新药创制"科技重大专项(2009ZX0901-007)

摘　　要：目的系统评价维奥欣(薯蓣皂苷)治疗脑血管疾病的疗效及安全性。方法搜集维奥欣治疗脑血管疾病随机对照试验的文献,由两名研究者独立选择试验、评价质量、提取数据,并交叉核对。使用RevMan 5.0软件进行Meta分析。结果共纳入9个RCT,844例脑血管疾病患者。结果显示维奥欣组与对照组总有效率比较为[84.9%vs62.4%,OR=5.41,95%CI(3.92,5.01),P<0.01];同时维奥欣可降低TC、TG、LDL-c水平,升高HDL-c水平,并具有统计学差异(P<0.05),其亦可改善全血高切,低切年度,红细胞比容,血浆年度及纤维蛋白原(P<0.05),并具有统计学差异,治疗过程仅有个别病例轻微胃肠功能不适。结论薯蓣皂苷片可显著改善脑血管患者症状,血脂代谢,改善血液流变学指标,治疗过程无明显不良反应。但由于纳入研究的方法质量和可能存在发表偏倚,有待进一步开展大样本、高质量、多中心的随机双盲对照试验来证实。Objective To evaluate the efficacy and safety of Shuyuzaogan tablet for cranial vascular disease.Methods Literatures were retrieved from Medline,EMBASE,Cochrane Library,CBM,VIP,CNKI databases by computer and from relevant Chinese medical journals by hand.Meta-analysis is conducted using RevMan 5.0 software.Results Shuyuzaogan tablet is superior to routine therapy [84.9%vs62.4%,OR=5.41,95%CI（3.92,5.01）,P0.01]in total efficacy.ShuyuzaoGan also can bring down TC,TG,LDL-c,while improving HDL-c,what is more,it also improve hemorheology,and there are statistically different between two groups.Only several cases have slight gastrointestinal discomfort.Conclusions Systematic review indicates that shuyuzaogan tablet is safe and effective for cranial vascular disease.However,due to the limited quality of the included studies,the results suggest that further and multi-centre and large-scale randomized double-blind control trials using shuyuzaogan tablet are needed.

关 键 词：薯蓣皂苷片 脑梗死 循证研究 

分 类 号：R743.3[医药卫生—神经病学与精神病学]